DS-1062a

DRUG3 trials

Sponsors

Daiichi Sankyo, Gustave Roussy, Cancer Campus, Grand Paris

Conditions

Advanced Non Small Cell Lung CancerMetastatic Lung CancerNon-small Cell Lung CancerUnresectable Non-small Lung Cancer

Phase 2

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

CompletedNCT04484142

Daiichi SankyoNon-small Cell Lung Cancer

Start: 2021-03-30End: 2026-02-04Updated: 2026-03-24

Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer

Active, not recruitingNCT04940325

Gustave Roussy, Cancer Campus, Grand ParisAdvanced Non Small Cell Lung Cancer, Metastatic Lung Cancer, Unresectable Non-small Lung Cancer

Start: 2021-05-12End: 2028-09-30Updated: 2025-11-26

Phase 3

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Active, not recruitingNCT04656652

Daiichi SankyoNon-small Cell Lung Cancer

Start: 2020-12-21End: 2027-02-15Updated: 2026-08-26

Related Papers

A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.

2025-06-124 citations

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

Journal of Clinical Oncology2025-01-0660 citations

TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer

Future Oncology2024-10-2911 citations

ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.

Journal of Clinical Oncology2024-06-0118 citations

Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05.

Journal of Clinical Oncology2024-06-0115 citations

Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd).

Journal of Clinical Oncology2024-06-018 citations

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

Journal of Clinical Oncology2024-03-2944 citations

Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung01

Pneumologie2024-03-013 citations

59P Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Nonsquamous (NSQ) histology in the phase III TROPION-Lung01 trial

ESMO Open2024-03-013 citations

TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2021-05-2029 citations

A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).

Journal of Clinical Oncology2021-05-2014 citations